The average of price targets set by Wall Street analysts indicates a potential upside of 28.1% in CareDx (CDNA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
BRISBANE, Calif., November 03, 2026--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the publication of a new analysis from the Kidney Allograft Outcomes AlloSure Registry (KOAR), a landmark multicenter study, in the journal Transplantation.
The precision medicine pioneer is helping to improve patient care.
CareDx (CDNA) delivered earnings and revenue surprises of +191.67% and +13.90%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
CareDx has staged a dramatic turnaround, resolving Medicare risk, returning to profitability, and initiating share buybacks. Read more on CDNA stock here.
CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
CareDx (CDNA) is up about 14% today after BTIG raised its price target from $60 to $74 and maintained its Buy rating. That’s a big move for a target bump – and there may be even more upside to be had… The detailsBTIG hosted CareDx’s CEO, CFO, and head of investor relations for investor meetings in Boston earlier this week, and came away more bullish: Target raised 23%, from $60 to $74Management sounded confident after the positive resolution of the transplant local coverage determination (this i
CMS aligns 2027 clinical lab fees with private payors to save $1 billion, yielding positive updates for CareDx and BillionToOne tests.
Here is how CareDx (CDNA) and Concentra Group (CON) have performed compared to their sector so far this year.
CareDx, BrightSpring and PACS have been highlighted in this Industry Outlook article.
CareDx (CDNA) stock has recently drawn attention after a sharp move in its share price. With returns over the past month and past 3 months well into double digits, investors are reassessing expectations. See our latest analysis for CareDx. Looking beyond the past month, CareDx has shown building momentum, with a 30.9% 1 month share price return, a 124.7% 3 month share price return and a 1 year total shareholder return of about 3.8x. The current share price of US$48.61 reflects a market that...
This is the newest page. Registered accounts read further back.